Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $20.2M | $0.00 | $14.0M | $14.0M | $15.2M | $24.4M | $26.0M | $7.14M |
| Revenue growth | — | — | — | -100.0% | — | 0.0% | 8.7% | 60.1% | 6.7% | -72.5% |
| Operating income | -$16.6M | -$21.4M | -$11.2M | -$24.4M | -$2.55M | -$111M | -$62.7M | -$71.9M | -$67.5M | -$114M |
| Operating margin | — | — | -55.5% | — | -18.2% | -794.4% | -411.9% | -295.4% | -259.6% | -1601.1% |
| Net income | -$17.0M | -$21.4M | -$10.4M | -$23.3M | -$3.48M | -$110M | -$60.5M | -$65.8M | -$63.7M | -$20.6M |
| Net margin | — | — | -51.6% | — | -24.8% | -786.4% | -397.7% | -270.0% | -245.1% | -288.3% |
| EPS (diluted) | -$24.52 | -$1.03 | -$0.31 | -$0.57 | -$1.76 | -$12.41 | -$2.69 | -$2.44 | -$2.36 | -$0.33 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$24.5K | -$18.9M | -$5.81M | -$23.9M | -$12.7M | -$22.4M | -$49.6M | -$59.7M | -$59.5M | -$97.4M |
| Capital expenditures | $113K | $8.90K | $37.9K | $237K | $19.0K | $46.0K | $444K | $3.97M | $1.65M | $552K |
| Free cash flow | -$138K | -$18.9M | -$5.85M | -$24.1M | -$12.7M | -$22.5M | -$50.1M | -$63.6M | -$61.2M | -$98.0M |
| Dividends paid | — | — | — | — | — | $4.41M | $0.00 | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.61M | $20.3M | $62.6M | $38.5M | $4.46M | $149M | $39.0M | $62.9M | $28.7M | $37.6M |
| Total assets | $2.40M | $21.0M | $64.1M | $39.9M | $18.8M | $158M | $184M | $132M | $70.3M | $151M |
| Total liabilities | — | — | $5.46M | $3.40M | $31.3M | $21.5M | $25.9M | $27.2M | $17.8M | $14.5M |
| Shareholders' equity | -$86.2M | $17.4M | $58.7M | -$9.09M | -$12.4M | $136M | $158M | $105M | $52.5M | $136M |
| Retained earnings | -$86.2M | -$109M | -$119M | -$142M | -$32.6M | -$143M | -$203M | -$269M | -$333M | -$353M |
| Shares (wtd avg diluted) | 1.24M | 27.1M | 40.6M | 40.6M | 2.54M | 8.92M | 22.5M | 26.9M | 27.0M | 61.9M |
Every figure is extracted from Whitehawk Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.